Silo Pharma Extends Exclusive Option Agreement for Homing Peptides

Rhea-AI Summary

Silo Pharma (OTC QB: SILO) announced the extension of its exclusive option agreement with the University of Maryland to explore joint-homing peptides for treating rheumatoid arthritis and other autoimmune diseases. This technology aims to enhance therapeutic delivery to diseased joints, improving treatment efficacy while minimizing systemic toxicity. CEO Eric Weisblum highlighted the potential of these peptides as a revolutionary drug delivery platform, emphasizing the need for innovative therapeutics for rare diseases.

Positive

• Extended exclusive option agreement with the University of Maryland for joint-homing peptides study.
• Potential to enhance therapeutic delivery and efficacy for rheumatoid arthritis treatment.
• May reduce systemic toxicity associated with current treatment methods.
• Opportunity to develop fusion imaging molecules and nanoparticles for studying arthritis.

Negative

• None.

Company Analyzing Efficacy of Novel Joint Homing Peptide ART-1 for Rheumatoid Arthritis and inflammation

Englewood Cliffs NJ, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTC QB: SILO), a developmental stage biopharmaceutical company, today announced that it has extended its exclusive option agreement with the University of Maryland, Baltimore to explore a novel invention generally known as Joint-homing peptides.  These peptides are being developed for use in the investigation and treatment of arthritogenic processes.

The ability of these targeted homing peptides in inflamed endothelium suggests they could be used to deliver therapeutics to specific diseased joints. This approach could enhance the therapeutic effect of current and future therapeutics and decrease potential systemic toxicity. These peptides also have the potential for the development of fusion imaging molecules and/or nanoparticles to study arthritic pathogenesis. In addition, these novel joint-homing peptides may be used to treat autoimmune diseases, including but not limited to Rheumatoid Arthritis.

“This extended option gives Silo further time and studies to access to a and confirm a potentially vital therapeutic that can also act as a drug delivery platform,” stated Eric Weisblum, Chairman and CEO of Silo Pharma. “The ability to deliver therapeutics directly to targeted areas of the body could be revolutionary.  The Joint-homing peptides have shown increased efficacy of treatment while reducing the amount of medication needed while also reducing harmful effects of treatment.  There is a tremendous need for creative and unique therapeutics for patients suffering from rare diseases.”

About Silo Pharma

Silo Pharma is a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as depression, PTSD, Alzheimer’s, Parkinson’s, and other rare neurological disorders. Silo’s mission is to identify assets to license and fund the research which we believe will be transformative to the well-being of patients and the health care industry. For more information, visit www.silopharma.com.

Safe Harbor and Forward-Looking Statements

This news release contains "forward-looking statements" within the meaning of the “safe-harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified by the use of words “could”, “believe”, “anticipate”, “intend”, “estimate”, “expect”, “may”, “continue”, “predict”, “potential” and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of Silo Pharma, Inc. (“Silo” or “the Company”) to differ materially from the results expressed or implied by such statements, including changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company’s technology platforms, retaining and expanding the Company’s customer base, fluctuations in consumer spending on the Company’s products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this presentation, whether as a result of new information, future events, or otherwise, after the date of this presentation or to reflect the occurrence of unanticipated events except as required by law.

Investor Relations Contact:                                       

Hayden IR

Brett Maas
646-536-7331
Email: brett@haydenir.com

FAQ

What is Silo Pharma's recent announcement about?

Silo Pharma announced the extension of an exclusive option agreement with the University of Maryland to further explore joint-homing peptides for rheumatoid arthritis treatment.

How does Silo Pharma's joint-homing peptide technology work?

The technology aims to deliver therapeutics directly to inflamed joints, potentially enhancing efficacy and minimizing systemic toxicity.

What autoimmune diseases could be treated with Silo Pharma's peptides?

The peptides could be used to treat rheumatoid arthritis and other autoimmune diseases.

Who is the CEO of Silo Pharma, and what did he say about the recent development?

Eric Weisblum is the CEO of Silo Pharma. He stated the extended agreement allows further studies on a potentially vital therapeutic and drug delivery platform.

What are the future prospects for Silo Pharma's joint-homing peptides?

The peptides have potential applications in developing fusion imaging molecules and nanoparticles, which could enhance understanding and treatment of arthritic diseases.